Due to Easter holiday, all delivery service requests will not be processed on Friday, April 10, 2020. Regular delivery schedule will resume on Monday, April 13, 2019.


  • $204.00


Description :Recombinant human OPG was expressed in E. coli cells and purified by proprietary chromatographic techniques.

Species :Human

Tag :

Expression System:E.coli

Sequence :

Genbank Number :NP_002537

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping :Stored at desiccated below -20oC. It is stable at 4oC between 2-7 days. For long term storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications :Cell Assay

Endotoxin Level :Less than 0.1 ng/ug (IEU/ug) of OPG.

Molecular Weight :~21 kDa

Gene Aliases :TNFRSF11B; TR1; OCIF; MGC29565

Scientific Background :OPG is an 11b member of tumor necrosis factor receptor superfamily which is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. OPG can act as a soluble factor in the regulation of bone mass and it may be useful in the treatment of osteoporosis associated with increased osteoclast activity (1). osteoprotegerin ( OPG) is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. OPG also play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential (2).

References :
1. Simonet, W. S. et.al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997.

2. Croucher, P. I. et.al: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540, 2001.

Product Sheets (By Lot #) :


Research Areas :Cardiovascular Disease, Inflammation, Inflammation, Cardiovascular Disease